Data on 2,185 patients with type 2 diabetes and stage 4 chronic kidney disease revealed those who received bardoxolone methyl had a higher incidence of cardiovascular-related death, heart failure and hospitalization compared with those taking a placebo. The drug was also associated with increased incidence of nonfatal myocardial infarction and nonfatal stroke in patients, researchers reported in the New England Journal of Medicine.

Related Summaries